Expert Review of Endocrinology and Metabolism This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study
CONCLUSIONS: Teneligliptin 20 mg could be considered as the preferred and most cost-effective agent among commonly used DPP4Is for the effective management of patients with T2DM in India.PMID:37232153 | DOI:10.1080/17446651.2023.2216279 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - May 26, 2023 Category: Endocrinology Authors: Harmanjit Singh Ekta Arora Seerat Narula Mandeep Singla Armaan Otaal Jatin Sharma Source Type: research

Intranasal oxytocin as a treatment for obesity: safety and efficacy
Expert Rev Endocrinol Metab. 2023 May 26:1-12. doi: 10.1080/17446651.2023.2216794. Online ahead of print.ABSTRACTINTRODUCTION: Known for its effect on labor and lactation and on emotional and social functions, oxytocin has recently emerged as a key modulator of feeding behavior and indeed suggested as a potential treatment for obesity. The potential positive effect of oxytocin on both metabolic and psychological-behavioral complications of hypothalamic lesions makes it a promising tool in the management of these conditions.AREAS COVERED: The aim of the present review article is to provide an overview of the mechanism of ac...
Source: Expert Review of Endocrinology and Metabolism - May 26, 2023 Category: Endocrinology Authors: Roberta Balestrino Marco Losa Luigi Albano Lina R Barzaghi Pietro Mortini Source Type: research

Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
Expert Rev Endocrinol Metab. 2023 May 18:1-13. doi: 10.1080/17446651.2023.2209176. Online ahead of print.ABSTRACTINTRODUCTION: Obesity is highly prevalent in the U.S. and is associated with an increased risk of major adverse cardiovascular events (MACE). Modalities for the management of obesity include lifestyle intervention, pharmacotherapy, and bariatric surgery.AREAS COVERED: This review describes the evidence on the effects of weight loss therapies on MACE risk. Lifestyle interventions and older antiobesity pharmacotherapies have been associated with <12% body weight reduction and no clear benefit to reduce MACE ris...
Source: Expert Review of Endocrinology and Metabolism - May 18, 2023 Category: Endocrinology Authors: Kevin C Maki Carol F Kirkpatrick David B Allison Kishore M Gadde Source Type: research